TB Alliance moves two novel tuberculosis drugs into human trials

October 11, 2017, Burness
This photomicrograph reveals Mycobacterium tuberculosis bacteria using acid-fast Ziehl-Neelsen stain; Magnified 1000 X. The acid-fast stains depend on the ability of mycobacteria to retain dye when treated with mineral acid or an acid-alcohol solution such as the Ziehl-Neelsen, or the Kinyoun stains that are carbolfuchsin methods specific for M. tuberculosis. Credit: public domain

TBA-7371 and sutezolid entered phase 1 clinical trials, TB Alliance announced today. Both compounds have proceeded through early preclinical development and were granted "Investigative New Drug" status by the U.S. Food and Drug Administration. The phase 1 clinical trials are presently ongoing.

"These two drugs give us great hope," said Dr. Mel Spigelman, president and CEO of TB Alliance. "As resistance to current TB treatments continues to grow, the need for compounds with no pre-existing resistance has become stark."

TBA-7371 is an antimicrobial compound developed by TB Alliance in collaboration with AstraZeneca. It is in a novel class of drugs known as DprE1 inhibitors, of which there are two other compounds in early . With no pre-existing resistance or cross-resistance with other TB drugs, TBA-7371 could have significant potential in the treatment of TB.

Sutezolid is an oxazolidinone, a class of drugs that has already shown evidence of clinical activity against TB. The oxazolidinone, linezolid, has shown promising results as part of the Nix-TB study testing a treatment for extensively -resistant TB (XDR-TB). However, the toxicity associated with long term administration of linezolid can be problematic. In March 2017, TB Alliance and the Medicines Patent Pool announced a sublicensing agreement for the development and commercialization of sutezolid for the treatment of TB.

"Several years ago, TB drug development was at a standstill," said Dr. Spigelman. "But now we have the backbone of new regimens—with bedaquiline and pretomanid—that we're testing in advanced along with other TB drugs. And while we still have a way to go before we arrive at a universal cure for this disease, we have building blocks coming through the research pipeline that show us we can get there."

Explore further: TB Alliance launches 'Nix-TB' clinical trial to test new XDR-TB treatment

Related Stories

TB Alliance launches 'Nix-TB' clinical trial to test new XDR-TB treatment

May 14, 2015
TB Alliance and its partners announced the start of a clinical trial of a new regimen to treat extensively drug-resistant tuberculosis (XDR-TB.) It is the first study to test an all-oral drug regimen, comprised of drugs with ...

Computational modeling of drug resistance to guide treatment decisions for HIV patients

September 20, 2017
A bioinformatic examination of HIV mutations documented in clinics could help guide the selection of antiretroviral therapies.

Trial for new drug-resistant TB treatment to begin

March 19, 2012
A global health alliance Monday unveiled plans for the first clinical tests of a new treatment regimen for tuberculosis, including for patients with resistance to existing multidrug programs.

Promising compound selected as drug candidate for tuberculosis

September 17, 2012
(Medical Xpress)—A New Zealand-designed compound that shows promise against treatment-resistance tuberculosis (TB) has been selected as a drug candidate by international non-profit drug developer the Global Alliance for ...

27 Phase III and 8 Phase II Alzheimer's drugs on track to launch in next five years

July 18, 2017
Twenty-seven Alzheimer's drugs in Phase III clinical trials and eight drugs in Phase II clinical trials may launch in the next five years, according to a revised Alzheimer's pipeline analysis presented today at the Alzheimer's ...

Recommended for you

Past encounters with the flu shape vaccine response

February 20, 2018
New research on why the influenza vaccine was only modestly effective in recent years shows that immune history with the flu influences a person's response to the vaccine.

Building better tiny kidneys to test drugs and help people avoid dialysis

February 16, 2018
A free online kidney atlas built by USC researchers empowers stem cell scientists everywhere to generate more human-like tiny kidneys for testing new drugs and creating renal replacement therapies.

Study suggests expanded range for emerging tick-borne disease

February 16, 2018
Human cases of Borrelia miyamotoi, a tick-borne infection with some similarities to Lyme disease, were discovered in the eastern United States less than a decade ago. Now new research led by the Yale School of Public Health ...

Expanding Hepatitis C testing to all adults is cost-effective and improves outcomes

February 16, 2018
According to a new study, screening all adults for hepatitis C (HCV) is a cost-effective way to improve clinical outcomes of HCV and identify more infected people compared to current recommendations. Using a simulation model, ...

Flu shot only 36 percent effective, making bad year worse (Update)

February 15, 2018
The flu vaccine is doing a poor job protecting older Americans and others against the bug that's causing most illnesses.

IFN-mediated immunity to influenza A virus infection influenced by RIPK3 protein

February 15, 2018
Each year, influenza kills half a million people globally with the elderly and very young most often the victims. In fact, the Centers for Disease Control and Prevention reported 37 children have died in the United States ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.